Researchers gave tumor-bearing mice six doses of a radioactive peptide and wiped out half of their prostate tumors. Whether the six doses arrived one a week or in two tight bursts a month apart made no measurable difference to the result.
The peptide is [177Lu]Lu-AU-SAR-M1, a radioligand: a small engineered molecule that homes in on cancer cells and irradiates them from a few cell-widths away. The preclinical study ↗, published September 5 in Biomedicine & Pharmacotherapy, tested a question this field usually skips. Not whether the drug works, but how its doses should be spaced out over time.
What a GRPR radioligand is
Radioligand therapy is the idea behind approved cancer drugs like Pluvicto and Lutathera. Take a peptide that sticks to a docking point found mostly on tumor cells, bolt a radioactive atom onto it, inject it, and let it deliver a short-range dose of radiation directly to the cancer while sparing most healthy tissue. The docking point here is GRPR, the gastrin-releasing peptide receptor. It sits in high numbers on the surface of most prostate and breast cancer cells and is scarce on normal tissue, which is what makes it a target worth aiming at. It is named after the gut and brain signaling peptide it normally listens for.
AU-SAR-M1 is an antagonist, meaning it plugs the receptor without switching it on. The field has been shifting from receptor-activating agonists to antagonists like this one because blocking versions occupy more binding sites and wash out of the blood and body faster, which the authors describe as giving cleaner tumor targeting with less collateral exposure. The radioactive payload is lutetium-177, a metal that emits short-range beta radiation, the same isotope used in the approved drugs.
The experiment
The team first traced where the drug went in the body to estimate the radiation dose each organ would absorb. Then they grew human prostate cancer cells (the GRPR-positive PC-3 line) as tumors in mice and split the animals into three arms. One group got six weekly injections of the radioligand, at 12 megabecquerels each (a megabecquerel is a unit of radioactivity). A second group got the same six injections, but bunched into two cycles of three weekly doses with a four-week gap in between. A third group got only the inert carrier fluid.
Both dosing schedules significantly slowed tumor growth and extended survival. Control mice lived a median of 37 days. Across the treated animals, about half the tumors were eradicated outright, and there was no significant difference between the weekly schedule and the bunched-and-spaced one. Neither regimen produced detectable bone marrow toxicity, the dose-limiting worry for radioligand therapy because irradiated blood-forming cells are what usually caps how much a patient can receive.
Why the schedule is the story
For a drug given once, dosing schedule is not a question. For radioligand therapy it is a real one. Each dose is a clinic visit under radiation-safety handling, with hospital scheduling, shielding, and waste rules attached. If the same tumor kill can be reached whether the doses are strung out weekly or compressed into two short courses, that is flexibility a treating center can use to fit the therapy around a patient's life and a facility's capacity, rather than being locked to one rigid cadence.
The honest limits are large. This is mice carrying human tumor cells, not people, and xenograft tumors are more uniform and more treatable than the real thing. The sample sizes in these experiments are small, and "no significant difference between schedules" can also mean the study was too small to detect a difference that exists. GRPR radioligands themselves are still early in humans. Agents like 177Lu-NeoB and 177Lu-RM2 are in phase 1 and phase 1/2 trials, positioned partly as an option for prostate cancers that do not carry PSMA, the target the approved Pluvicto hits. None of them is close to answering the schedule question in patients.
Peptidemodel hosts cards for the peptide radioligand family that this work sits in. Earlier this month the section covered a different lever on the same class, a redesigned somatostatin radioligand that lingered longer on its receptor ↗ to deliver more dose per injection. That study pushed on residence time. This one pushes on timing between injections. Both are the unglamorous engineering that decides whether a radioactive peptide becomes a usable therapy or stays a promising mouse result.